These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24282988)

  • 1. Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma.
    Devarakonda S; Morgensztern D; Govindan R
    Oncology (Williston Park); 2013 Sep; 27(9):899-906. PubMed ID: 24282988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovative Clinical Trials: The LUNG-MAP Study.
    Steuer CE; Papadimitrakopoulou V; Herbst RS; Redman MW; Hirsch FR; Mack PC; Ramalingam SS; Gandara DR
    Clin Pharmacol Ther; 2015 May; 97(5):488-91. PubMed ID: 25676724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging drugs for squamous cell lung cancer.
    Cheng H; Shcherba M; Kandavelou K; Liang Y; Liu H; Perez-Soler R
    Expert Opin Emerg Drugs; 2015 Mar; 20(1):149-60. PubMed ID: 25557559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New developments in the treatment of squamous cell lung cancer.
    Filipits M
    Curr Opin Oncol; 2014 Mar; 26(2):152-8. PubMed ID: 24441504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic alterations as the basis for resistance to targeted therapies.
    Blair BG; Bardelli A; Park BH
    J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Challenge of gene-based personalized lung cancer medicine].
    Seki Y; Kohno T
    Nihon Rinsho; 2015 Aug; 73(8):1373-7. PubMed ID: 26281692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic landscape of squamous cell carcinoma of the lung.
    Morgensztern D; Devarakonda S; Govindan R
    Am Soc Clin Oncol Educ Book; 2013; ():348-53. PubMed ID: 23714544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis.
    Dacic S
    Expert Rev Mol Diagn; 2007 Jan; 7(1):77-86. PubMed ID: 17187486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular prognostication of non-small cell lung cancer.
    Tsao MS; Jablons DM
    Semin Thorac Cardiovasc Surg; 2013; 25(1):4-7. PubMed ID: 23800523
    [No Abstract]   [Full Text] [Related]  

  • 10. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
    Ludwig WD
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The changing face of percutaneous image-guided biopsy: molecular profiling and genomic analysis in current practice.
    Marshall D; Laberge JM; Firetag B; Miller T; Kerlan RK
    J Vasc Interv Radiol; 2013 Aug; 24(8):1094-103. PubMed ID: 23806383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospects for molecular staging of non-small-cell lung cancer from genomic alterations.
    Tomaszek SC; Huebner M; Wigle DA
    Expert Rev Respir Med; 2010 Aug; 4(4):499-508. PubMed ID: 20658911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional drug-gene interactions in lung cancer.
    Smida M; Nijman SM
    Expert Rev Mol Diagn; 2012 Apr; 12(3):291-302. PubMed ID: 22468819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive genomic characterization of squamous cell lung cancers.
    Cancer Genome Atlas Research Network
    Nature; 2012 Sep; 489(7417):519-25. PubMed ID: 22960745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?
    Arnedos M; Vielh P; Soria JC; Andre F
    J Pathol; 2014 Jan; 232(2):274-82. PubMed ID: 24114621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
    Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
    Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic alterations defining NSCLC subtypes and their therapeutic implications.
    Pikor LA; Ramnarine VR; Lam S; Lam WL
    Lung Cancer; 2013 Nov; 82(2):179-89. PubMed ID: 24011633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epistatic interactions and drug response.
    Weigelt B; Reis-Filho JS
    J Pathol; 2014 Jan; 232(2):255-63. PubMed ID: 24105606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of cell-type specific profiles in tissues and isolated cells from squamous cell carcinomas of the lung.
    Hawthorn L; Stein L; Panzarella J; Loewen GM; Baumann H
    Lung Cancer; 2006 Aug; 53(2):129-42. PubMed ID: 16757060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [2014 classification of lung carcinomas: latest entities and clinical implications. Case 1: Poorly differentiated non small cell lung carcinoma: interpretation of small biopsy specimens].
    Vignaud JM
    Ann Pathol; 2013 Oct; 33(5):306-10. PubMed ID: 24238239
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.